Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study

OBJECTIVE:To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity. METHODS:In this prospective, single-arm, dose-titration study (NCT01603459), patients (18–80 years) with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2017-04, Vol.88 (14), p.1321-1328
Hauptverfasser:	Wissel, Jörg, Bensmail, Djamel, Ferreira, Joaquim J, Molteni, Franco, Satkunam, Lalith, Moraleda, Susana, Rekand, Tiina, McGuire, John, Scheschonka, Astrid, Flatau-Baqué, Birgit, Simon, Olivier, Rochford, Edward T.J, Dressler, Dirk, Simpson, David M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Botulinum Toxins, Type A - adverse effects Botulinum Toxins, Type A - immunology Dose-Response Relationship, Drug Extremities Female Humans Lung Diseases - etiology Male Middle Aged Muscle Spasticity - complications Muscle Spasticity - drug therapy Neuromuscular Agents - adverse effects Retrospective Studies Vital Signs - drug effects Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!